ALKS: Elixirxton demonstrates strong efficacy, safety, and dosing flexibility for narcolepsy and hypersomnolence

Elixirxton shows high efficacy and safety in NT1 and NT2, with flexible dosing strategies emerging from Vibrance-2 data. Phase 3 trials will focus on tailored dosing, and the competitive landscape is expected to support multiple orexin agonists.

Based on Alkermes plc [ALKS] Piper Sandler 37th Annual Healthcare Conference Audio Transcript — Dec. 4 2025